Is ZYME's EPS performance improving or declining long-term?

**Zymeworks Inc. (ZYME) is experiencing a decline in EPS performance in the short-term, but there are signs of potential improvement in the long-term.** 1. **Current Financial Performance**: Zymeworks has reported an EPS of -$0.31 for Q4 2024, which is a negative figure indicating a loss. This missed the estimated EPS of -$0.03, reflecting a poorer-than-expected performance. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |ZYME|ZYME.O|Zymeworks|2024 Q1|-13.513513513513512|-0.42|185| |ZYME|ZYME.O|Zymeworks|2024 Q2|35.526315789473685|-0.49|185| |ZYME|ZYME.O|Zymeworks|2024 Q3|4.878048780487796|-0.39|185| 2. **Analysts' Forecasts**: Analysts have forecasted a decline in EPS in the near term, with estimates for Q1 2025 showing a loss of $0.51 per share. This suggests that the company's financial performance is expected to remain under pressure in the immediate future. 3. **Long-Term Outlook**: Despite the current challenges, analysts have made substantial upgrades to their estimates for this year, with a reduced loss per share anticipated to be $1.40 in 2025. This indicates a potential improvement in EPS performance as we move into the future. 4. **Strategic Adjustments**: The company has been making strategic adjustments, such as reducing research and general administrative expenses. These efforts could lead to improved financial performance over time. 5. **Cash Position**: Zymeworks has a strong cash position, with $324.2 million as of December 31, 2024. This provides a solid foundation for the company to navigate through the current financial challenges and invest in its future growth. In conclusion, while Zymeworks is facing a challenging period with its EPS performance, the company's strategic adjustments, cash reserves, and analysts' long-term forecasts suggest optimism for potential improvement in the future.